CHEMOMETEC

Chemometec Raises FY27 Revenue & EBITDA Guidance, Boosting Investor Confidence

Chemometec raises FY27 revenue and EBITDA guidance after strong Q1, boosting investor confidence and reinforcing its market‑leading cell‑counting solutions.

CHEMOMETEC
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

05/10/2026, 12:40

3 minutes to read

Chemometec Completes Share Buy‑Back, Boosting Shareholder Value and Growth Confidence

ChemoMetec completes share buy‑back, boosting shareholder value and signaling confident growth in its cell‑counting & regenerative tech portfolio.

CHEMOMETEC
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

02/10/2026, 18:28

3 minutes to read